<DOC>
	<DOC>NCT01564901</DOC>
	<brief_summary>This prospective, observational, multicenter study will assess the efficacy and safety of RoActemra/Actemra (tocilizumab) on the use of glucocorticoids in patients with moderate to severe rheumatoid arthritis and an inadequate response to previous disease-modifying antirheumatic drugs or anti-TNF. Data will be collected for 36 weeks.</brief_summary>
	<brief_title>An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Treated With Glucocorticoids</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Adults patients, over 18 years of age Patients with moderate to severe rheumatoid arthritis (RA) Patients on a stable dose of prednisone or equivalent (&gt;/=7.5 mg/day) for at least 4 weeks before study inclusion Patients previously treated with RoActemra/Actemra Any contraindication to RoActemra/Actemra</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>